Episode Details

DeepHealth’s Saige-Dx recently received FDA 510(k) clearance for analyzing digital breast tomosynthesis (DBT) mammograms. We unpack the public summary to see how this AI tool uses prior screening exams to reduce false positive alerts, and break down the exact testing demographics behind the clearance.

Key points

• Saige-Dx is an AI software cleared as a concurrent reading aid to identify soft tissue lesions and calcifications in DBT mammograms.
• This new clearance expands upon the predicate device by adding compatibility with Siemens systems and the ability to process prior exams.
• Processing prior exams was validated to reduce false positive marks per image by dropping false positive bounding boxes when a matching prior finding is identified.
• Performance was evaluated in two retrospective, standalone studies involving 2,425 cases and 684 cases, proving non-inferiority in AUC.
• The FDA clearance strictly labels Saige-Dx as an adjunct tool, warning that decisions should not be made solely based on its analysis.

Source: FDA 510(k) summary K253825: Saige-Dx (DeepHealth) - U.S. Food and Drug Administration, 2026

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-deephealth-saige-dx-using-prior-exams-to-drop-false-6031cd